(Q35824537)

10 August 2017

1 reference

title

Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? (English)

1 reference

systemic lupus erythematosus

10 August 2017

main subject

0 references

author name string

J Schiffenbauer

series ordinal

1

1 reference

10 August 2017

L S Simon

series ordinal

2

1 reference

10 August 2017

language of work or name

1 reference

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

13

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

398-405

1 reference

A conceptual framework for clinical trials in SLE and other multisystem diseases

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1033OA

Methodological issues of corticosteroid use in SLE clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1033OA

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1033OA

Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1033OA

Impact of disease activity and cumulative damage on the health of lupus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1033OA

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1033OA

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1033OA

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1033OA

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1033OA

Quality of life and economic evaluation in SLE clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1033OA

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1033OA

Cyclophosphamide in lupus nephritis: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1033OA

Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1033OA

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU1033OA

10.1191/0961203303LU1033OA

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference